ACE and cancer: For the management of hypertension not induced by cancer therapies, angiotensin-converting enzyme inhibitors (ACEI) were the most common antihypertensive drug prescribed by cardiologists and oncologists (52.9 and 39.5%, respectively) followed by angiotensin receptor blockers (ARB) (28.4 and 26.3%, respectively).